fda compounding semaglutide warning letters september 2025 A company called Nomida has received an letter for offering for sale injectable weight-loss treatments. None of their offerings are FDA-approved. Nomida is allegedly selling unapproved and Tirzepatide "kits" FDA alerts health care providers,

However, persistent or distressing changes should be discussed with a healthcare provider

In the majority of cases, labiaplasty is done to alter the shape of the labia as per patients desires or correct significant discrepancies in size and shape between the two lips

The off-the-shelf product is administered four times a year and has the potential for use for DMD cardiomyopathy regardless of the specific DMD-causing gene mutation

Personalized medicine approaches may eventually match individual patients to optimal compounds based on genetic, metabolic, or other biomarkers

A survey of GLP-1 users conducted by Morgan Stanley Research found that they reduce calorie intake meaningfully, with 50% reporting reductions of 20% or more